Pfizer Research Grant Request for Proposals: The Role of RSV in Functional Decline and Healthcare Dependency in Hospitalized Adults
Pfizer Inc. is funding research on how RSV infection leads to functional decline and healthcare dependency in hospitalized adults in Italy.
Funder: Pfizer Inc.
Due Dates: October 19, 2026: Submission Deadline
Funding Amounts: Up to EUR 150,000 per project; total available budget EUR 300,000; maximum project duration 18 months.
Summary: Supports research on the impact of RSV infection on functional decline and healthcare dependency in hospitalized adults in Italy.
Key Information: Both PI and institution must be based in Italy; late applications will not be reviewed.
Description
This grant opportunity from Pfizer aims to advance real-world evidence on the broader impacts of respiratory syncytial virus (RSV) infection in hospitalized adults in Italy. The program encourages independent research projects that investigate the functional decline, increased healthcare dependency, and non-respiratory complications experienced by older adults and those with pre-existing vulnerabilities following RSV-related hospitalization. The goal is to inform better risk stratification, targeted prevention, and post-discharge care strategies for at-risk adult populations, ultimately improving outcomes and quality of life.
